Status: Recruiting
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
Participants needed: 100
Trial details
Phase: Phase 1Age: 13+Biological sex: AllType: InterventionalSponsor: Newave Pharmaceutical IncUpdated: May 5, 2026Locations: 8
Eligibility criteria
Relapsed or refractory low risk tumor lysis CLL/SLL subjects (ALC < 25 x 109 cel... [+43]
Subjects who have undergone autologous/allogeneic hematopoietic stem cell transp... [+28]